On 29 July 2021, the CMA announced that it had imposed a fine of £101 million on Advanz Pharma for abusing its dominant position by charging excessive and unfair prices for liothyronine tablets between 2009 and 2017.
On 29 July 2021, the CMA announced that it had imposed a fine of £101 million on Advanz Pharma for abusing its dominant position by charging excessive and unfair prices for liothyronine tablets between 2009 and 2017.
WE VALUE YOUR PRIVACY
This site uses cookies and full details are set out in our Cookie Policy. Essential Cookies are always on; to accept Analytics Cookies, click "I agree to all cookies."